BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Average Recommendation of "Moderate Buy" by Brokerages

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the ten analysts that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $16.70.

Several research analysts have recently weighed in on the stock. Needham & Company LLC reiterated a "buy" rating and set a $17.00 price objective on shares of BioCryst Pharmaceuticals in a report on Wednesday, June 25th. Barclays increased their price objective on shares of BioCryst Pharmaceuticals from $8.00 to $11.00 and gave the stock an "equal weight" rating in a report on Wednesday, May 7th. Royal Bank Of Canada reissued an "outperform" rating and set a $13.00 target price on shares of BioCryst Pharmaceuticals in a research report on Monday, June 30th. Bank of America increased their target price on shares of BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the stock a "buy" rating in a research report on Tuesday, July 1st. Finally, Cantor Fitzgerald started coverage on shares of BioCryst Pharmaceuticals in a research report on Tuesday, April 29th. They set an "overweight" rating and a $20.00 target price for the company.

Institutional Trading of BioCryst Pharmaceuticals

Several large investors have recently bought and sold shares of the company. Vanguard Group Inc. grew its position in BioCryst Pharmaceuticals by 7.8% in the fourth quarter. Vanguard Group Inc. now owns 21,890,422 shares of the biotechnology company's stock valued at $164,616,000 after acquiring an additional 1,583,826 shares in the last quarter. Alkeon Capital Management LLC grew its position in BioCryst Pharmaceuticals by 1.7% in the first quarter. Alkeon Capital Management LLC now owns 7,214,021 shares of the biotechnology company's stock valued at $54,105,000 after acquiring an additional 120,199 shares in the last quarter. Millennium Management LLC grew its position in BioCryst Pharmaceuticals by 382.6% in the first quarter. Millennium Management LLC now owns 3,812,874 shares of the biotechnology company's stock valued at $28,597,000 after acquiring an additional 3,022,769 shares in the last quarter. Assenagon Asset Management S.A. grew its position in BioCryst Pharmaceuticals by 25,631.2% in the second quarter. Assenagon Asset Management S.A. now owns 3,620,637 shares of the biotechnology company's stock valued at $32,441,000 after acquiring an additional 3,606,566 shares in the last quarter. Finally, Caligan Partners LP grew its position in shares of BioCryst Pharmaceuticals by 16.0% during the fourth quarter. Caligan Partners LP now owns 2,995,932 shares of the biotechnology company's stock worth $22,529,000 after buying an additional 412,347 shares in the last quarter. Institutional investors and hedge funds own 85.88% of the company's stock.

BioCryst Pharmaceuticals Price Performance

Shares of BCRX stock opened at $8.59 on Thursday. The firm has a market cap of $1.80 billion, a P/E ratio of -33.04, a PEG ratio of 2.46 and a beta of 1.04. BioCryst Pharmaceuticals has a 1-year low of $6.02 and a 1-year high of $11.31. The firm's 50-day simple moving average is $9.97 and its 200-day simple moving average is $8.66.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.